Vayu Maini Rekdal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vayu Maini Rekdal has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Emily P. Balskus
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA
4 shared publications - Peter James Turnbaugh
Department of Microbiology & Immunology, University of California, San Francisco, USA
3 shared publications - Elizabeth N. Bess
Department of Chemistry, University of California, Irvine, California 92617, United States
2 shared publications - Jordan E. Bisanz
Department of Biochemistry and Molecular Biology, Pennsylvania State University
2 shared publications Sina Kiamehr
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, United States
2 shared publicationsBradley A. Schmidt
Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
1 shared publication
Latest Publications
- 25 June 2026
- Published by American Society for Microbiology in Microbiology and Molecular Biology Reviews
- Vol. 90 (2) , e0017825
Toward synthetic biology in mushroom-forming Agaricomycete fungi: from tools to applications
SUMMARY: Mushroom-forming Agaricomycete fungi underpin global nutrient cycling and carbon sequestration, and support large and growing markets across food, medicinal supplements, and biomaterials. Yet most commercial and research uses still rely on wild-type strains, highlighting the opportunity for genetic engineering to expand possibilities for both fundamental research and biotechnological applications. In this review, we highlight progress toward synthetic biology in Agaricomycetes, and outline the main barriers that limit predictable genetic engineering. We emphasize engineering constraints unique to mushroom biology, including complex sexual cycles, heterokaryosis, and strain instability during transformation and outgrowth. We then transition to gene expression bottlenecks: the scarcity of characterized promoters and terminators, the challenges for gene integration posed by the condensed nature of Agaricomycete genomes, and the effects of introns and specific sequence motifs. Finally, drawing inspiration from progress in related fungi and other eukaryotes, we highlight the priorities for the field: systematic cross-species evaluation of genetic parts, development of more sophisticated gene-editing strategies, higher-throughput screening methods, and the establishment of a unifying model system. These advances would enable new possibilities in the study and use of Agaricomycetes, establishing these elusive organisms as programmable platforms for sustainable biomanufacturing, designer biomaterials, climate solutions, and mechanistic studies of fungal biology.
- 25 June 2026
- Published by American Society for Microbiology in Microbiology and Molecular Biology Reviews
- Vol. 90 (2) , e0017825
Toward synthetic biology in mushroom-forming Agaricomycete fungi: from tools to applications
SUMMARY: Mushroom-forming Agaricomycete fungi underpin global nutrient cycling and carbon sequestration, and support large and growing markets across food, medicinal supplements, and biomaterials. Yet most commercial and research uses still rely on wild-type strains, highlighting the opportunity for genetic engineering to expand possibilities for both fundamental research and biotechnological applications. In this review, we highlight progress toward synthetic biology in Agaricomycetes, and outline the main barriers that limit predictable genetic engineering. We emphasize engineering constraints unique to mushroom biology, including complex sexual cycles, heterokaryosis, and strain instability during transformation and outgrowth. We then transition to gene expression bottlenecks: the scarcity of characterized promoters and terminators, the challenges for gene integration posed by the condensed nature of Agaricomycete genomes, and the effects of introns and specific sequence motifs. Finally, drawing inspiration from progress in related fungi and other eukaryotes, we highlight the priorities for the field: systematic cross-species evaluation of genetic parts, development of more sophisticated gene-editing strategies, higher-throughput screening methods, and the establishment of a unifying model system. These advances would enable new possibilities in the study and use of Agaricomycetes, establishing these elusive organisms as programmable platforms for sustainable biomanufacturing, designer biomaterials, climate solutions, and mechanistic studies of fungal biology.
- Open Access
Distinct Classes of Gut Bacterial Molybdenum-Dependent Enzymes Produce Urolithins
Urolithin A is an anti-aging and anti-inflammatory gut bacterial metabolite derived from ellagic acid (EA), a polyphenol abundant in berries and nuts. The conversion of EA to urolithin A involves multiple chemically challenging phenol dehydroxylation steps that produce urolithins with varying bioactivities. Despite their biological and chemical significance, the bacterial enzymes responsible for urolithin production remain unidentified. Here, we use differential gene expression analysis, anaerobic protein expression, and enzyme assays to identify members of two distinct molybdenum enzyme families (the DMSO reductase family and the xanthine oxidase family) capable of regioselective dehydroxylation and urolithin generation. These two enzyme families have distinct substrate requirements, suggesting they employ different catalytic mechanisms for phenol dehydroxylation. Multi-omics analysis of a human cohort uncovers decreased levels of urolithin A and genes encoding urolithin A-producing enzymes in patients with inflammatory bowel disease (IBD), implying reduced health effects of EA consumption in this setting. Together, this study elucidates the molecular basis of urolithin production, expands the known enzymatic repertoire of the human gut microbiome, and suggests a potential link between gut bacterial urolithin production and host inflammation. Significance statement The human gut microbiome modulates the health effects of dietary compounds by modifying their chemical structures. For example, gut microbes extensively metabolize polyphenols, a group of diverse plant-derived compounds associated with positive health outcomes. Urolithin A, a gut bacterial metabolite derived from a polyphenol abundant in berries and nuts, exhibits potent anti-inflammatory activity. However, the gut bacterial enzymes involved in its production remain largely unknown. Here, we report urolithin-producing gut bacterial enzymes, including four phenol dehydroxylases from two distinct molybdenum-dependent enzyme families. Analyzing human gut microbiomes suggests a potential link between genes encoding these enzymes and host inflammation. Together, our findings fully map urolithin A production to enzymes, increasing our understanding of how the gut microbiome can alter the impacts of diet on human health.
Open AccessDistinct Classes of Gut Bacterial Molybdenum-Dependent Enzymes Produce Urolithins
Urolithin A is an anti-aging and anti-inflammatory gut bacterial metabolite derived from ellagic acid (EA), a polyphenol abundant in berries and nuts. The conversion of EA to urolithin A involves multiple chemically challenging phenol dehydroxylation steps that produce urolithins with varying bioactivities. Despite their biological and chemical significance, the bacterial enzymes responsible for urolithin production remain unidentified. Here, we use differential gene expression analysis, anaerobic protein expression, and enzyme assays to identify members of two distinct molybdenum enzyme families (the DMSO reductase family and the xanthine oxidase family) capable of regioselective dehydroxylation and urolithin generation. These two enzyme families have distinct substrate requirements, suggesting they employ different catalytic mechanisms for phenol dehydroxylation. Multi-omics analysis of a human cohort uncovers decreased levels of urolithin A and genes encoding urolithin A-producing enzymes in patients with inflammatory bowel disease (IBD), implying reduced health effects of EA consumption in this setting. Together, this study elucidates the molecular basis of urolithin production, expands the known enzymatic repertoire of the human gut microbiome, and suggests a potential link between gut bacterial urolithin production and host inflammation. Significance statement The human gut microbiome modulates the health effects of dietary compounds by modifying their chemical structures. For example, gut microbes extensively metabolize polyphenols, a group of diverse plant-derived compounds associated with positive health outcomes. Urolithin A, a gut bacterial metabolite derived from a polyphenol abundant in berries and nuts, exhibits potent anti-inflammatory activity. However, the gut bacterial enzymes involved in its production remain largely unknown. Here, we report urolithin-producing gut bacterial enzymes, including four phenol dehydroxylases from two distinct molybdenum-dependent enzyme families. Analyzing human gut microbiomes suggests a potential link between genes encoding these enzymes and host inflammation. Together, our findings fully map urolithin A production to enzymes, increasing our understanding of how the gut microbiome can alter the impacts of diet on human health.
- Open Access
- 18 February 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
A widely distributed metalloenzyme class enables gut microbial metabolism of host- and diet-derived catechols
Catechol dehydroxylation is a central chemical transformation in the gut microbial metabolism of plant- and host-derived small molecules. However, the molecular basis for this transformation and its distribution among gut microorganisms are poorly understood. Here, we characterize a molybdenum-dependent enzyme from the human gut bacteriumEggerthella lentathat dehydroxylates catecholamine neurotransmitters. Our findings suggest that this activity enablesE. lentato use dopamine as an electron acceptor. We also identify candidate dehydroxylases that metabolize additional host- and plant-derived catechols. These dehydroxylases belong to a distinct group of largely uncharacterized molybdenum-dependent enzymes that likely mediate primary and secondary metabolism in multiple environments. Finally, we observe catechol dehydroxylation in the gut microbiotas of diverse mammals, confirming the presence of this chemistry in habitats beyond the human gut. These results suggest that the chemical strategies that mediate metabolism and interactions in the human gut are relevant to a broad range of species and habitats.
- 18 February 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Open AccessA widely distributed metalloenzyme class enables gut microbial metabolism of host- and diet-derived catechols
Catechol dehydroxylation is a central chemical transformation in the gut microbial metabolism of plant- and host-derived small molecules. However, the molecular basis for this transformation and its distribution among gut microorganisms are poorly understood. Here, we characterize a molybdenum-dependent enzyme from the human gut bacteriumEggerthella lentathat dehydroxylates catecholamine neurotransmitters. Our findings suggest that this activity enablesE. lentato use dopamine as an electron acceptor. We also identify candidate dehydroxylases that metabolize additional host- and plant-derived catechols. These dehydroxylases belong to a distinct group of largely uncharacterized molybdenum-dependent enzymes that likely mediate primary and secondary metabolism in multiple environments. Finally, we observe catechol dehydroxylation in the gut microbiotas of diverse mammals, confirming the presence of this chemistry in habitats beyond the human gut. These results suggest that the chemical strategies that mediate metabolism and interactions in the human gut are relevant to a broad range of species and habitats.
- Open Access
A widely distributed metalloenzyme class enables gut microbial metabolism of host- and diet-derived catechols
Catechol dehydroxylation is a central chemical transformation in the gut microbial metabolism of plant- and host-derived small molecules. However, the molecular basis for this transformation and its distribution among gut microorganisms are poorly understood. Here, we characterize a molybdenum-dependent enzyme from the prevalent human gut bacterium Eggerthella lenta that specifically dehydroxylates catecholamine neurotransmitters available in the human gut. Our findings suggest that this activity enables E. lenta to use dopamine as an electron acceptor under anaerobic conditions. In addition to characterizing catecholamine dehydroxylation, we identify candidate molybdenum-dependent enzymes that dehydroxylate additional host-and plant-derived small molecules. These gut bacterial catechol dehydroxylases are specific in their substrate scope and transcriptional regulation and belong to a distinct group of largely uncharacterized molybdenum-dependent enzymes that likely mediate both primary and secondary metabolism in multiple environments. Finally, we observe catechol dehydroxylation in the gut microbiotas of diverse mammals, suggesting that this chemistry is present in habitats beyond the human gut. Altogether, our data reveal the molecular basis of catechol dehydroxylation among gut bacteria and suggest that the chemical strategies that mediate metabolism and interactions in the human gut are relevant to a broad range of species and habitats.
Open AccessA widely distributed metalloenzyme class enables gut microbial metabolism of host- and diet-derived catechols
Catechol dehydroxylation is a central chemical transformation in the gut microbial metabolism of plant- and host-derived small molecules. However, the molecular basis for this transformation and its distribution among gut microorganisms are poorly understood. Here, we characterize a molybdenum-dependent enzyme from the prevalent human gut bacterium Eggerthella lenta that specifically dehydroxylates catecholamine neurotransmitters available in the human gut. Our findings suggest that this activity enables E. lenta to use dopamine as an electron acceptor under anaerobic conditions. In addition to characterizing catecholamine dehydroxylation, we identify candidate molybdenum-dependent enzymes that dehydroxylate additional host-and plant-derived small molecules. These gut bacterial catechol dehydroxylases are specific in their substrate scope and transcriptional regulation and belong to a distinct group of largely uncharacterized molybdenum-dependent enzymes that likely mediate both primary and secondary metabolism in multiple environments. Finally, we observe catechol dehydroxylation in the gut microbiotas of diverse mammals, suggesting that this chemistry is present in habitats beyond the human gut. Altogether, our data reveal the molecular basis of catechol dehydroxylation among gut bacteria and suggest that the chemical strategies that mediate metabolism and interactions in the human gut are relevant to a broad range of species and habitats.
- Top Cited PapersOpen Access
- 14 June 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 364 (6445) , 1055-+
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
The dope on l -dopa metabolism: The efficacy of l -dopa treatment for Parkinson's disease is hugely variable between individuals, depending on the composition of their microbiota. l -Dopa is decarboxylated into active dopamine, but if the gut microbiota metabolize l -dopa before it crosses the blood-brain barrier, medication is ineffective. Maini Rekdal et al. found that different species of bacterium are involved in l -dopa metabolism (see the Perspective by O'Neill). Tyrosine decarboxylase (TDC) from Enterococcus faecalis and dopamine dehydroxylase (Dadh) from Eggerthella lenta A2 sequentially metabolized l -dopa into m -tyramine. The microbial l -dopa decarboxylase can be inactivated by ( S )-α-fluoromethyltyrosine (AFMT), which indicates possibilities for developing combinations of Parkinson's drugs to circumvent microbial inactivation. Science , this issue p. eaau6323 ; see also p. 1030
- 14 June 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 364 (6445) , 1055-+
Top Cited PapersOpen AccessDiscovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
The dope on l -dopa metabolism: The efficacy of l -dopa treatment for Parkinson's disease is hugely variable between individuals, depending on the composition of their microbiota. l -Dopa is decarboxylated into active dopamine, but if the gut microbiota metabolize l -dopa before it crosses the blood-brain barrier, medication is ineffective. Maini Rekdal et al. found that different species of bacterium are involved in l -dopa metabolism (see the Perspective by O'Neill). Tyrosine decarboxylase (TDC) from Enterococcus faecalis and dopamine dehydroxylase (Dadh) from Eggerthella lenta A2 sequentially metabolized l -dopa into m -tyramine. The microbial l -dopa decarboxylase can be inactivated by ( S )-α-fluoromethyltyrosine (AFMT), which indicates possibilities for developing combinations of Parkinson's drugs to circumvent microbial inactivation. Science , this issue p. eaau6323 ; see also p. 1030
- 24 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (464)
Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea
Increased amino acids in the dysbiotic gut influences susceptibility to Clostridioides difficile infection in mice and humans.
- 24 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (464)
Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea
Increased amino acids in the dysbiotic gut influences susceptibility to Clostridioides difficile infection in mice and humans.
- Top Cited PapersOpen Access
- 23 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6344)
Chemical transformation of xenobiotics by the human gut microbiota
One person's meat is another's poison: The human gut is packed with actively metabolizing microorganisms. These have a transformative effect on what we ingest—whether food, drugs, or pollutants. Koppelet al.review the distinguishing features of microbial xenobiotic metabolism, its interaction with somatic metabolism, and interindividual variation. Depending on the functional composition of microorganisms in the gut, the subsequent products may have nutritionally beneficial effects, modify pharmaceuticals, or be toxic. All of these consequences of our companion microbes can have important impacts on human health and well-being.Science, this issue p.eaag2770
- 23 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6344)
Top Cited PapersOpen AccessChemical transformation of xenobiotics by the human gut microbiota
One person's meat is another's poison: The human gut is packed with actively metabolizing microorganisms. These have a transformative effect on what we ingest—whether food, drugs, or pollutants. Koppelet al.review the distinguishing features of microbial xenobiotic metabolism, its interaction with somatic metabolism, and interindividual variation. Depending on the functional composition of microorganisms in the gut, the subsequent products may have nutritionally beneficial effects, modify pharmaceuticals, or be toxic. All of these consequences of our companion microbes can have important impacts on human health and well-being.Science, this issue p.eaag2770